Prospects for new antibiotics: a molecule-centered perspective (Q38113689)

29 August 2017

Prospects for new antibiotics: a molecule-centered perspective (English)

1 reference

29 August 2017

0 references

Christopher T Walsh

1

1 reference

PubMed ID

23756684

29 August 2017

Timothy A Wencewicz

series ordinal

2

1 reference

29 August 2017

12 June 2013

1 reference

The Journal of Antibiotics

29 August 2017

1 reference

29 August 2017

67

1 reference

29 August 2017

7-22

1 reference

29 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/ja.2013.49

29 August 2017

0 references

cites work

Letter: New antibacterial agent via photofluorination of a bacterial cell wall constituent.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Organofluorine synthesis via photofluorination: 3-fluoro-D-alanine and 2-deuterio analogue, antibacterials related to the bacterial cell wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Suicide substrates for the alanine racemase of Escherichia coli B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Suicide substrates, mechanism-based enzyme inactivators: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Mechanism of inactivation of alanine racemase by beta, beta, beta-trifluoroalanine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Crystallization and preliminary X-ray crystallographic studies of UDP-N-acetylenolpyruvylglucosamine reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The structure of the substrate-free form of MurB, an essential enzyme for the synthesis of bacterial cell walls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

(E)-enolbutyryl-UDP-N-acetylglucosamine as a mechanistic probe of UDP-N-acetylenolpyruvylglucosamine reductase (MurB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Kinetic characterization of wild-type and S229A mutant MurB: evidence for the role of Ser 229 as a general acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

X-ray crystal structures of the S229A mutant and wild-type MurB in the presence of the substrate enolpyruvyl-UDP-N-acetylglucosamine at 1.8-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Intracellular steps of bacterial cell wall peptidoglycan biosynthesis: enzymology, antibiotics, and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Vancomycin resistance: structure of D-alanine:D-alanine ligase at 2.3 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Active site mapping of Escherichia coli D-Ala-D-Ala ligase by structure-based mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Enzymes of vancomycin resistance: the structure of D-alanine-D-lactate ligase of naturally resistant Leuconostoc mesenteroides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Vancomycin resistance in enterococci: reprogramming of the D-ala-D-Ala ligases in bacterial peptidoglycan biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Glycopeptide and lipoglycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Vancomycin assembly: nature's way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Tailoring enzymes that modify nonribosomal peptides during and after chain elongation on NRPS assembly lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Polyketide and nonribosomal peptide antibiotics: modularity and versatility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The chemical versatility of natural-product assembly lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Total biosynthesis: in vitro reconstitution of polyketide and nonribosomal peptide pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Genetics and assembly line enzymology of siderophore biosynthesis in bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Natural products version 2.0: connecting genes to molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Humans as the world's greatest evolutionary force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

A Critical Evaluation of Nalidixic Acid in Urinary-Tract Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Infectious disease. Approval of novel TB drug celebrated--with restraint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The antibiotic resistome: the nexus of chemical and genetic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The shared antibiotic resistome of soil bacteria and human pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Vancomycin resistance: decoding the molecular logic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Genetics and mechanisms of glycopeptide resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Sampling the antibiotic resistome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Quinupristin/dalfopristin: a therapeutic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Characterization of the polymyxin B resistome of Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Tuberculosis: the drug development pipeline at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Antibiotics for emerging pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Antibiotics in the clinical pipeline in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Drugs for bad bugs: confronting the challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Target-oriented and diversity-oriented organic synthesis in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The discovery of antibacterial agents using diversity-oriented synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Towards the optimal screening collection: a synthesis strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Organic synthesis toward small-molecule probes and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structure Guided Development of Novel Thymidine Mimetics Targeting Pseudomonas aeruginosa Thymidylate Kinase: From Hit to Lead Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Synthesis and inhibitory activity of thymidine analogues targeting Mycobacterium tuberculosis thymidine monophosphate kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Synthesis and Evaluation of α-Thymidine Analogues as Novel Antimalarials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Synthesis and evaluation of 5'-modified thymidines and 5-hydroxymethyl-2'-deoxyuridines as Mycobacterium tuberculosis thymidylate kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Isolating "uncultivable" microorganisms in pure culture in a simulated natural environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Siderophores from neighboring organisms promote the growth of uncultured bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Uncultured microorganisms as a source of secondary metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

New antibiotics from bacterial natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The impact of bacterial genomics on natural product research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Discovery of FabH/FabF inhibitors from natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Abyssomicin C-A polycyclic antibiotic from a marine Verrucosispora strain as an inhibitor of the p-aminobenzoic acid/tetrahydrofolate biosynthesis pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

How many antibiotics are produced by the genus Streptomyces?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Genome mining for novel natural product discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Advances in the understanding and use of the genomic base of microbial secondary metabolite biosynthesis for the discovery of new natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Genomic analyses lead to novel secondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Significant natural product biosynthetic potential of actinorhizal symbionts of the genus frankia, as revealed by comparative genomic and proteomic analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

A genomic approach to the cryptic secondary metabolome of the anaerobic world

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Fungal secondary metabolites - strategies to activate silent gene clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Epigenome manipulation as a pathway to new natural product scaffolds and their congeners

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Recent advances in awakening silent biosynthetic gene clusters and linking orphan clusters to natural products in microorganisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Metagenomic approaches to natural products from free-living and symbiotic organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Tetarimycin A, an MRSA-active antibiotic identified through induced expression of environmental DNA gene clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The A-Z of bacterial translation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Daptomycin: mechanisms of action and resistance, and biosynthetic engineering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Antagonism of chemical genetic interaction networks resensitize MRSA to β-lactam antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Bugs, drugs and chemical genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

New syntheses of E7389 C14-C35 and halichondrin C14-C38 building blocks: double-inversion approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

A head-to-head comparison of eneamide and epoxyamide inhibitors of glucosamine-6-phosphate synthase from the dapdiamide biosynthetic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Mechanism of action of anticandidal dipeptides containing inhibitors of glucosamine-6-phosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Moenomycin family antibiotics: chemical synthesis, biosynthesis, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Crystal structure of a peptidoglycan glycosyltransferase suggests a model for processive glycan chain synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Crystal structure of the membrane-bound bifunctional transglycosylase PBP1b from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural Analysis of the Contacts Anchoring Moenomycin to Peptidoglycan Glycosyltransferases and Implications for Antibiotic Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Characterization of the active site of S. aureus monofunctional glycosyltransferase (Mtg) by site-directed mutation and structural analysis of the protein complexed with moenomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Functional and Structural Analysis of a Key Region of the Cell Wall Inhibitor Moenomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The total synthesis of moenomycin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Complete characterization of the seventeen step moenomycin biosynthetic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Tuning the moenomycin pharmacophore to enable discovery of bacterial cell wall synthesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Lipid II as a target for antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Crystal structures of the complexes between vancomycin and cell-wall precursor analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Redesign of glycopeptide antibiotics: back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Synthesis and Characterization of the Arylomycin Lipoglycopeptide Antibiotics and the Crystallographic Analysis of Their Complex with Signal Peptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Broadening the spectrum of β-lactam antibiotics through inhibition of signal peptidase type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Myxobacterium-produced antibiotic TA (myxovirescin) inhibits type II signal peptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Imaging mass spectrometry and genome mining via short sequence tagging identified the anti-infective agent arylomycin in Streptomyces roseosporus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Initial efforts toward the optimization of arylomycins for antibiotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Total synthesis of myxovirescin A1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Solid phase synthesis of globomycin and SF-1902 A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Biosynthesis of new lipopentapeptides by an engineered strain of Streptomyces sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Myxovirescin A biosynthesis is directed by hybrid polyketide synthases/nonribosomal peptide synthetase, 3-hydroxy-3-methylglutaryl-CoA synthases, and trans-acting acyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Mutational analysis of the myxovirescin biosynthetic gene cluster reveals novel insights into the functional elaboration of polyketide backbones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Incorporation of nonmethyl branches by isoprenoid-like logic: multiple beta-alkylation events in the biosynthesis of myxovirescin A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Biosynthesis of lipid A in Escherichia coli: identification of UDP-3-O-[(R)-3-hydroxymyristoyl]-alpha-D-glucosamine as a precursor of UDP-N2,O3-bis[(R)-3-hydroxymyristoyl]-alpha-D-glucosamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Lipopolysaccharide endotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Species-Specific and Inhibitor-Dependent Conformations of LpxC: Implications for Antibiotic Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The Escherichia coli Lpt Transenvelope Protein Complex for Lipopolysaccharide Export Is Assembled via Conserved Structurally Homologous Domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Cytoplasmic ATP hydrolysis powers transport of lipopolysaccharide across the periplasm in E. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Disulfide rearrangement triggered by translocon assembly controls lipopolysaccharide export

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Regulated assembly of the transenvelope protein complex required for lipopolysaccharide export

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Lipoprotein LptE is required for the assembly of LptD by the beta-barrel assembly machine in the outer membrane of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The complex that inserts lipopolysaccharide into the bacterial outer membrane forms a two-protein plug-and-barrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Nonconsecutive disulfide bond formation in an essential integral outer membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Characterization of the two-protein complex in Escherichia coli responsible for lipopolysaccharide assembly at the outer membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Development of an activity assay for discovery of inhibitors of lipopolysaccharide transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Transport of lipopolysaccharide across the cell envelope: the long road of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Proteins required for lipopolysaccharide assembly in Escherichia coli form a transenvelope complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structure and function of an essential component of the outer membrane protein assembly machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: a new family of broad-spectrum antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

From natural product to marketed drug: the tiacumicin odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Inhibition of bacterial RNA polymerase by streptolydigin: stabilization of a straight-bridge-helix active-center conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The RNA polymerase "switch region" is a target for inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structures of RNA polymerase-antibiotic complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural basis for transcription inhibition by tagetitoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

ATP-binding site of bacterial enzymes as a target for antibacterial drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Diarylquinolines target subunit c of mycobacterial ATP synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Dysregulation of bacterial proteolytic machinery by a new class of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Clp ATPases and ClpP proteolytic complexes regulate vital biological processes in low GC, Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Acyldepsipeptide antibiotics induce the formation of a structured axial channel in ClpP: A model for the ClpX/ClpA-bound state of ClpP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

An inhibitor of FtsZ with potent and selective anti-staphylococcal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

The antibacterial cell division inhibitor PC190723 is an FtsZ polymer-stabilizing agent that induces filament assembly and condensation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Comparison of small molecule inhibitors of the bacterial cell division protein FtsZ and identification of a reliable cross-species inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Aminoglycoside antibiotics in the 21st century.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Discovery of LFF571: an investigational agent for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Analysis of Fluoromethyl Group Chirality Establishes a Common Stereochemical Course for the Enolpyruvyl Transfers Catalyzed by EPSP Synthase and UDP-GlcNAc Enolpyruvyl Transferase†

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Structural Basis of the Action of Pulvomycin and GE2270 A on Elongation Factor Tu†,‡

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

Characteristics of beta, beta-difluoroalanine and beta, beta, beta -trifluoroalanine as suicide substrates for Escherichia coli B alanine racemase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Overexpression, purification, and mechanistic study of UDP-N-acetylenolpyruvylglucosamine reductase

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

An enzyme-substrate complex involved in bacterial cell wall biosynthesis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Purification and characterization of the D-alanyl-D-alanine-adding enzyme from Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Determinants for differential effects on D-Ala-D-lactate vs D-Ala-D-Ala formation by the VanA ligase from vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Mining microbial genomes for new natural products and biosynthetic pathways

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Designing antimicrobial peptides: form follows function.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

https://api.crossref.org/works/10.1038%2FJA.2013.49

1 reference

7 January 2021

Myxovirescin analogues via macrocyclic ring-closing metathesis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Structure-activity relationships of globomycin analogues as antibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

3-Hydroxy-3-Methylglutaryl-CoA-Like Synthases Direct the Formation of Methyl and Ethyl Side Groups in the Biosynthesis of the Antibiotic Myxovirescin A

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

What counters antibiotic resistance in nature?

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.49

7 January 2021

Identifiers

DOI

10.1038/JA.2013.49

1 reference

PubMed ID

23756684

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23756684